Customize GFS12 Antibody

Description

Clarification of Terminology

G12 Antibody: Targets immunotoxic prolamins in wheat, barley, rye, and some oats, critical for celiac disease detection .
SF12 Antibody: A broadly neutralizing HIV-1 antibody targeting the silent face of the envelope glycoprotein gp120 .

No sources mention "GFS12," suggesting a potential typographical error or a compound not covered in the provided literature.

Characterization of G12 Antibody

If the query refers to the G12 antibody, the following data are relevant:

Epitope Specificity

G12 recognizes immunogenic peptides containing the hexameric epitope QPQLPY and related variants (e.g., QPQLPF, QPQQPY) . These sequences are found in α-gliadin and other prolamins linked to celiac disease.

Cross-Reactivity

Target	Reactivity	Clinical Relevance
Wheat	High (immunotoxic prolamins)	Primary source of gluten in celiac disease
Barley	High (similar epitopes)	Common contaminant in gluten-free foods
Rye	High (shared epitopes)	Cross-contamination risk in processed foods
Oats (select varieties)	Variable (depends on cultivar)	Potential source of immunogenic peptides for sensitive celiac patients

Performance Metrics

Sensitivity: Detects 80–95% of immunogenic peptides in celiac disease .
Limitations: Does not detect all 1,000+ known immunogenic gluten peptides .

Characterization of SF12 Antibody (HIV-1 Neutralization)

If the query refers to SF12 (a broadly neutralizing HIV antibody), key findings include:

Mechanism of Action

Target: N448-linked glycan on the silent face of HIV-1 envelope glycoprotein gp120 .
Neutralization Breadth: ~62% across viral clades, particularly clade AE .

Comparative Analysis of G12 vs. SF12 Antibodies

Parameter	G12 Antibody	SF12 Antibody
Target Disease	Celiac disease	HIV-1 infection
Epitope Type	Peptide (QPQLPY variants)	Glycan (N448-linked)
Cross-Reactivity	Wheat, barley, rye, oats	Broadly neutralizing across HIV clades
Clinical Application	Gluten detection in foods	Vaccine/therapeutic candidate for HIV prevention/treatment

Potential Confusion with Other Antibodies

2G12 Antibody: A domain-exchanged HIV antibody targeting high-mannose glycans on gp120 .
- Key Difference: 2G12 binds a glycan cluster, while SF12 targets a single glycan site .
BMS-986012: A nonfucosylated IgG1 antibody targeting FucGM1 in small-cell lung cancer .

Recommendations for Further Inquiry

Verify Nomenclature: Confirm whether "GFS12" refers to a specific variant (e.g., fusion protein or modified antibody).
Explore Patent Literature: GFS12 may be a proprietary compound not covered in open-access sources.
Consult Specialized Databases: Use resources like the Antibody Structure Database (AbDb) to identify structural analogs.

Product Specs

Buffer

Preservative: 0.03% ProClin 300; Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Lead Time

14-16 week lead time (made-to-order)

Synonyms

GFS12 antibody; BCHD antibody; At5g18525 antibody; T28N17.10Protein GFS12 antibody; EC 2.7.10.- antibody; BEACH domain-containing protein D antibody; BEACH-domain homolog D antibody; GREEN FLUORESCENT SEED 12 antibody

Target Names

GFS12

Uniprot No.

F4JY12

Target Background

Function

The GFS12 antibody targets a protein that appears to primarily suppress BCHC1. BCHC1 negatively regulates protein storage vacuole (PSV) trafficking and plant effector-triggered immunity (ETI). While GFS12 is required for ETI, it does not appear to be necessary for cell death.

Database Links

KEGG: ath:AT5G18525

STRING: 3702.AT5G18525.1

UniGene: At.27063

Protein Families

Protein kinase superfamily, Tyr protein kinase family

Tissue Specificity

Weakly expressed in the cotyledons of germinating seedlings. Restricted to the vascular tissues of cotyledons. Detected in root tips, apical meristem, young flower buds and receptacles.

Q&A

FAQs for Researchers on Antibody GFS12
Note: No direct references to "GFS12 Antibody" were identified in the provided sources. Below is a synthesized framework based on general antibody research methodologies and challenges, informed by the search results.

Advanced Research Questions

How can computational tools resolve contradictions in epitope mapping data?

Strategies:
- Combine crosslinking-coupled mass spectrometry (to identify proximal residues) with alanine-scanning mutagenesis .
- Use RosettaAntibodyDesign (RAbD) to model antibody-antigen interactions and predict energetically favorable binding interfaces .
- Validate predictions via cryo-EM or X-ray crystallography for high-resolution epitope characterization .

What methodologies address discrepancies between in vitro and in vivo antibody efficacy?

Factor	In Vitro Approach	In Vivo Adjustment
Target Affinity	SPR/binding assays	Adjust dosing based on PK/PD modeling
Glycosylation Impact	Glycan microarray profiling	Use glycoengineered animal models
Fc Effector Function	ADCC/CDC assays	Engineer Fc regions for optimal effector activity

How do cell-free platforms accelerate antibody discovery workflows?

Workflow:
- Generate DNA templates via PCR or synthetic gene fragments .
- Express antibody fragments (e.g., scFv, Fab) using cell-free protein synthesis (CFPS) systems .
- Screen binding affinity directly in the reaction mixture via epitope binning or high-throughput SPR .
- Advantages: Reduces timeline from weeks to days; ideal for pandemic-responsive pipelines .

Methodological Considerations from Key Studies

Antibody Engineering:
- Affinity maturation via phage display (e.g., combinatorial VH/VL pairing) improves potency by 10- to 100-fold .
- Fc engineering (e.g., hinge region modifications) optimizes effector functions like ADCC .
Data Interpretation:
- For glycan-targeting antibodies (e.g., anti-HIV 2G12), ensure synthetic glycoconjugates mimic natural glycan topology to avoid false positives .
- Use mathematical modeling (e.g., receptor occupancy simulations) to predict clinical dosing regimens .

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

GFS12 Antibody